Mississauga, Ontario – Rumours that Toronto-based Vasogen Incorporated’s new Celacade treatment for heart failure, also referred to as Acclaim II, is a failed drug and that clinical trials for their new product has reached the failure stage, apparently its new Celacade system has suffered a striking reversal of study requirements that are required by the U.S. Food and Drug Administration, has apparently started the rumour mill spinning at breakneck speed today about the possible closure of the firm and the total loss of 125 high paid employees of the troubled firm.

This comes directly after the company announced it was cutting 85 percent of its current workforce and seeking alternatives to save cash because of the recent announcement of the failure of their Celacade System, but that about 15 employees would remain after the restructuring move.

We were able to contact representatives of Vasogen, who wished to stay unnamed, for comment about the current situation.  Vasogen officials stated that the company needs to restructure to find about 3 million for planned restructuring in the second half of the year, thus the cost cutting actions to allow them to achieve their goals to allow the company to stay afloat.  They stated that they would be discontinuing operational and financial support for European commercialization and exploring alternates for their cash strapped European marketing partner, Grupo Ferrer.

In conclusion, bringing a new drug onto the marketplace is a time consuming and expensive adventure for most pharmaceutical companies, the hoops they need to jump through, the years of trials, often mean in the end the product never makes it to market.  If Vasogen’s new Celacade System works and can provide sufferers of ailments with treatments that will help alleviate the symptoms and effects of their afflictions, then eventually it will get approved, but time will tell.